secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2022-02-09T23:59:59+00:00
Accession:  0001564590-22-004414
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto forms R&D Committee, boosts non-executive Chair option grant to 36,000 shares
--------------------------------------------------------------------------------

- R&D Committee established; members receive $7,500/yr retainer, Chair gets additional $7,500/yr.
- Non-Executive Chair annual option grant increased from 18,000 to 36,000 shares; other directors remain at 18,000.
- Initial equity award of 18,000 options vests over 36 months; annual award vests over 12 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000156459022004414/0001564590-22-004414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000156459022004414/glto-8k_20220203.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-004414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer